Merck KGaA (MKGAF) is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.

The company is focused on oncology, multiple sclerosis, infertility, growth disorders, selected cardiovascular and metabolic diseases, women’s and children’s health, cough and cold as well as everyday health protection.

The company reports its results in three business sectors – Healthcare, Life Science and Performance Materials.

The acquisition of Sigma-Aldrich led the company to gain access to an attractive set of established brands along with an efficient supply chain to support the delivery of over 300,000 products, thereby enabling it to serve life science customers all over the world.

The company’s lead candidate, avelumab, is being evaluated in phase III studies for several cancer indications, in collaboration with Pfizer.

We have highlighted some of the key stats from this just-revealed announcement below:

Earnings: The company’s second-quarter 2016 earnings per American Depositary Receipt (ADR) came in at 80 cents, compared to the year-ago figure of 90 cents.

Revenue: The company posted revenues of $4.3 billion in the reported quarter.

Key Stats: All three business units continued to perform well. Organic sales growth increased 5.1%, driven by Life Science and Healthcare segments. The acquisition of Sigma-Aldrich boosted sales in the reported quarter.

Guidance: For 2016, the company expects net sales in the range of €14.9–€15.1 billion. Backed by Sigma-Aldrich acquisition, the company expects a positive portfolio effect on sales in the low double-digit percentage range. Unfavorable foreign exchange is projected to impact sales by 3–5%.

MERCK KGAA Price

MERCK KGAA Price | MERCK KGAA Quote